1MRK Stock Overview
Operates as a science and technology company in Germany. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 1MRK from our risk checks.
Merck KGaA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €139.60 |
52 Week High | €176.30 |
52 Week Low | €134.60 |
Beta | 0.71 |
11 Month Change | -15.21% |
3 Month Change | -17.76% |
1 Year Change | -12.48% |
33 Year Change | -36.89% |
5 Year Change | 31.02% |
Change since IPO | 50.59% |
Recent News & Updates
Recent updates
Shareholder Returns
1MRK | IT Pharmaceuticals | IT Market | |
---|---|---|---|
7D | -8.2% | -5.4% | -1.2% |
1Y | -12.5% | 3.2% | 12.7% |
Return vs Industry: 1MRK underperformed the Italian Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: 1MRK underperformed the Italian Market which returned 14.5% over the past year.
Price Volatility
1MRK volatility | |
---|---|
1MRK Average Weekly Movement | 3.7% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 4.1% |
10% most volatile stocks in IT Market | 7.2% |
10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: 1MRK has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1MRK's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1668 | 62,255 | Belen Garijo Lopez | www.merckgroup.com/en |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
1MRK fundamental statistics | |
---|---|
Market cap | €60.87b |
Earnings (TTM) | €2.70b |
Revenue (TTM) | €20.96b |
22.6x
P/E Ratio2.9x
P/S RatioIs 1MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1MRK income statement (TTM) | |
---|---|
Revenue | €20.96b |
Cost of Revenue | €8.64b |
Gross Profit | €12.33b |
Other Expenses | €9.63b |
Earnings | €2.70b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 06, 2025
Earnings per share (EPS) | 6.20 |
Gross Margin | 58.80% |
Net Profit Margin | 12.86% |
Debt/Equity Ratio | 37.8% |
How did 1MRK perform over the long term?
See historical performance and comparison